WeeklyTrader Posted - 4 weeks ago

A big move up is coming! $CERT None RSI: 46.79% 50-day MA: $11.58 200-day MA: $15.23

WeeklyTrader Posted - 1 month ago

The market loves $CERT! RSI: 46.61% 50-day MA: $11.84 200-day MA: $15.4

swingingtech Posted - 1 month ago

$IYH $TXG $IONS $CERT https://wallstreetwaves.com/analysts-project-10-growth-potential-for-iyh/

ManosDeDiamante07 Posted - 1 month ago

$CERT Trying some here with a tight stop

insiderbuyingselling Posted - 1 month ago

$CERT new insider selling: 5409 shares. http://insiderbuyingselling.com/?t=CERT

themacromindset Posted - 1 month ago

$CERT Certara Completes Acquisition of Chemaxon $CERT

Profitrip Posted - 09/27/24

$SNAP $BMEA $CERT $VIST $WYNN on my upgrade scan so far!

basscat12 Posted - 09/27/24

$BMEA $CERT $WYNN Morning Mash-Up, page 4, Highlighted Analyst Activity. courtesy @TheTradeXchange , the Best Squawk On The Street" and presented with @Vegas1 to help prepare for today's market!

Stock_Titan Posted - 2 months ago

$CERT Certara & Ichnos Glenmark Innovation Collaboration Optimizes Dosing Strategy for Potential First-In-Class Cancer Drug https://www.stocktitan.net/news/CERT/certara-ichnos-glenmark-innovation-collaboration-optimizes-dosing-yf3rvw97j62u.html

PenkeTrading Posted - 2 months ago

I found you an Oversold RSI (Relative Strength Index) on the daily chart of Certara Inc. Is that bullish or bearish? $CERT #Certara #RsiOversold #NASDAQ

Ergashev_96 Posted - 2 months ago

$CERT nice stock

InsiderPeek Posted - 2 months ago

$CERT Chief Commercal Officer Pedersen Leif E sold 51.2k shares for $578.3k (ownership down 33.94%) insiderpeek.com/company/CERT

kinderspiel Posted - 3 months ago

unusual stock volume $CERT 1,853,148 average 605,810 (x 3.1) $DH 1,836,579 average 1,044,384 (x 1.8) $ALTS 1,826,545 average 192,346 (x 9.5) $GCTS 1,785,842 average 36,672 (x 48.7) $NMHI 1,774,795 average 594,747 (x 3)

Stock_Titan Posted - 3 months ago

$CERT Certara Launches Phoenix™ Version 8.5 Drug Development Software https://www.stocktitan.net/news/CERT/certara-launches-phoenix-version-8-5-drug-development-nol3fv0odibj.html

Stock_Titan Posted - 3 months ago

$CERT Certara Reports Second Quarter 2024 Financial Results https://www.stocktitan.net/news/CERT/certara-reports-second-quarter-2024-financial-ognm8y5majf6.html

NVDAMillionaire Posted - 07/30/24

$CERT Certara, Inc. (CERT): Leveraging Biosimulation to Drive Pharmaceutical Innovation http://beyondspx.com/2024/07/30/certara-inc-cert-leveraging-biosimulation-to-drive-pharmaceutical-innovation/

EingeLTrade Posted - 4 months ago

Higher lows and looking ready for a 20% gain 🚀 $CERT

DonCorleone77 Posted - 4 months ago

$CERT Certara price target lowered to $20 from $23 at KeyBanc KeyBanc lowered the firm's price target on Certara to $20 from $23 and keeps an Overweight rating on the shares. The firm's credit card data continues to show healthy utilization levels across hospital systems post the Change Healthcare outage, with hospital customer levels up high single digits in May and June year over year, but the ongoing robust employment data for healthcare systems keeps the firm wary of potential spending for hospital-exposed names, the analyst tells investors in a research note.

DonCorleone77 Posted - 4 months ago

$CERT Certara reaffirms FY24 adjusted EPS view 41c-46c, cosensus 43c Certara, excluding Chemaxon, is reiterating 2024 revenue, adjusted EBITDA margin, and adjusted diluted earnings per share guidance consistent with the May 7th earnings call. Following transaction close, Certara will update its 2024 guidance to include contribution from Chemaxon and expects to maintain its 2024 adjusted EBITDA margin guidance of 31%-33%.

DonCorleone77 Posted - 4 months ago

$CERT Certara signs a definitive agreement to acquire Chemaxon Certara announced it has signed a definitive agreement to acquire Chemaxon, a leading provider of cheminformatics software. The transaction is expected to close in the second half of 2024, subject to regulatory approval and other customary closing conditions. Chemaxon develops leading software products for chemical structure drawing, property prediction, search, and analysis. Used by research scientists globally, Chemaxon software helps to digitize the design, make, test and analyze lifecycle to discover the best new chemical leads. Certara and Chemaxon have had a long-term partnership spanning ten years. In 2024, Chemaxon is expected to generate software revenue greater than $20M. Chemaxon has a revenue growth profile comparable to Certara's software business and is expected to reach an adjusted EBITDA margin near Certara's corporate average by the end of 2025.

Stock_Titan Posted - 4 months ago

$CERT Certara to Acquire Chemaxon to Strengthen Drug Discovery Software Portfolio https://www.stocktitan.net/news/CERT/certara-to-acquire-chemaxon-to-strengthen-drug-discovery-software-56dvqslu713v.html

Stock_Titan Posted - 4 months ago

$CERT Certara to Report Second Quarter 2024 Financial Results on August 6th, 2024 https://www.stocktitan.net/news/CERT/certara-to-report-second-quarter-2024-financial-results-on-august-odbbmkl2sy4w.html

DonCorleone77 Posted - 06/28/24

$CERT Certara price target lowered to $16 from $18 at Barclays Barclays analyst Luke Sergott lowered the firm's price target on Certara to $16 from $18 and keeps an Equal Weight rating on the shares ahead of the Q2 report. The analyst says the company's intra-quarter commentary has lowered expectations for a bioprocessing destocking recovery, biotech funding has stalled and capex spending is bouncing along the bottom due to constrained pharma budgets. The firm continues to favor contract research organizations on valuation, and bioprocessing names "as it is still the only market that is improving."

Stocksrunner Posted - 5 months ago

$CERT enters oversold territory, indicating potential buying opportunity as sentiment turns excessively bearish. Watch for signs of reversal or bounce.

DonCorleone77 Posted - 5 months ago

$CERT Certara launches next-generation CoAuthor generative AI software Certara unveiled its next-generation CoAuthor regulatory writing software. CoAuthor is an advanced writing platform designed for medical writers. It combines generative AI, document templates, Microsoft Word integration, and structured content authoring tools. CoAuthor accelerates the creation of regulatory documents while maintaining a "human in the loop" approach to the use of generative AI.

TFars Posted - 5 months ago

$CERT I’m seeing more smart people on here posting losses. Let’s post those L’s. We take the losses quick and ride winners! Let’s normalize taking losses.

Wigglyick Posted - 5 months ago

$CERT Stopped out for an L

DonCorleone77 Posted - 6 months ago

$CERT Certara backs FY24 adjusted EPS view 41c-46c, consensus 43c Backs FY24 revenue view $385M-$400M, consensus $388.45M. Full year adjusted EBITDA is expected to grow with expected margin to be in the range of 31-33%. Fully diluted shares are expected to be in the range of 160 million to 162 million.

DonCorleone77 Posted - 6 months ago

$CERT Certara reports Q1 adjusted EPS 10c, consensus 10c Reports Q1 revenue $96.7M, consensus $93.64M. am pleased with our first quarter financial results, steered by solid execution across both software and services," said William F. Feehery, Chief Executive Officer. "To date, the strategic investments in additional software capabilities and commercial expansion have progressed on plan, and customer interest for Certara's products and services remains high. Certara is well positioned to grow in 2024 as biosimulation becomes more widely used across the drug development industry."

Stock_Titan Posted - 6 months ago

$CERT Certara Reports First Quarter 2024 Financial Results https://www.stocktitan.net/news/CERT/certara-reports-first-quarter-2024-financial-f1095umxl3ue.html